Singapore markets closed

XOMA Corporation (XOMA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
25.03-0.48 (-1.88%)
At close: 04:00PM EDT
25.85 +0.82 (+3.28%)
After hours: 05:32PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close25.51
Open25.51
Bid0.00 x 0
Ask25.99 x 100
Day's range24.81 - 26.19
52-week range13.48 - 27.00
Volume21,733
Avg. volume15,754
Market cap291.314M
Beta (5Y monthly)0.57
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.16 (8.61%)
Ex-dividend date02 Apr 2024
1y target estN/A
All
News
  • GlobeNewswire

    XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

    EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in New York, NY. Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat taking place at 11:00 AM ET. The presentation can be accessed at https://bit.l

  • GlobeNewswire

    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

    Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA’s balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well

  • GlobeNewswire

    XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

    Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women’s health assets: Ovaprene®, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6%, a potential first-in-category Phase 3-ready candidate for female sexual arousal disorder Bayer HealthCare